MyopiaPhase 2NCT06161311
Baseline Relative Peripheral Refraction in Myopia Control
A Phase 2 study testing DIMS lenses in people with Myopia, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
Trial summary
Myopia has become a world concern and its prevalence has increased in recent decades. Myopic defocus has been applied for slowing down the axial elongation and myopia progression, which is mainly based on the theory of simultaneous competing defocus and peripheral optics. Read more about this study
- Who is it for?
- Ages 6 to 9 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia
- What is being tested?
- DIMS lenses
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Dec 2023to 3 Apr 2025
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 9 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Age at enrolment: 6-9 years
- Spherical equivalent refraction (SER): -0.75 to -5.00 Diopters (D)
- Astigmatism: -1.50 D or less
- Anisometropia: 1.50 D or less
- Spectacle best-corrected monocular visual acuity (VA): 0.00 logMAR or better
Who cannot join
- Ocular and systemic abnormalities might affect visual functions or refractive development
- Prior use of any drugs or optical devices of myopia control treatment.
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site, 1 recruiting
- Recruiting
Optometry Research Clinic
Hong Kong, Hong Kong, nol
Tsz Wing Leung, PhD, 27664268, jeffrey.TW.leung@polyu.edu.hk
About this study
Official title: The Influence of Baseline Relative Peripheral Refraction in Myopia Control Using Myopic Defocus
Myopia has become a world concern and its prevalence has increased in recent decades. Myopic defocus has been applied for slowing down the axial elongation and myopia progression, which is mainly based on the theory of simultaneous competing defocus and peripheral optics. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses impose myopic defocus in the central or peripheral retina, with myopia progression being retarded by 50% to 60%. However, the optimal amount of myopic defocus has not yet been determined. Relative peripheral refraction (RPR) is used to indicate the difference between peripheral refraction and central refraction. Previous studies showed that retinal shape determined RPR, and baseline RPR may influence the myopia control efficacy using DIMS lenses on myopic children. It is still unclear if any other unknown factor influenced the final myopia control outcome in these young children with myopic RPR at baseline. Unlike our previous study8 that bias on hyperopic RPR children (myopic RPR, n = 27; hyperopic RPR, n = 52), this study is a case-control study with the same sample size for each RPR group. We will also include younger children who are more prone to have myopic RPR and develop high myopia. The results should provide new insight into the myopia control strategy in early-onset myopic children.
In the current study, we will investigate the influence of baseline RPR in myopia retardation using DIMS lenses among young myopic children.
Read more
This will ba a 1-year prospective clinical trial. Through G*Power (version 3.1.9.6) calculation, 80 healthy myopic subjects (40 myopic RPR vs 40 hyperopic RPR) aged 5-9 years should be needed. After screened by inclusion criteria, eligible participants will be assigned to wear DIMS lenses for 1 year (12 months, 8 hour per day, 7 days per week). This study includes 5 visits: Visit 1: baseline, Visit 2: lens dispensing, Visit 3: 2-week follow-up, Visit 4: 6-month follow-up, and Visit 5: 12-month follow-up. All eye examinations will be carried out in the Optometry Research Centre (A137), the School of Optometry, the Hong Kong Polytechnic University. The main data collection, including refractive error, axial length, related ocular parameters will be measured at baseline, 6-month and 1-year visits. At the lens dispensing and 2-week follow-up visits, vision acuity testing and computer scanning of posterior eyes will be measured. New DIMS lens will be replaced and upgraded if the equivalent sphere of refraction (SER) is changed or visual acuity change.
The following data will be statistically analyzed. The primary outcome data include the difference in change in SER with cycloplegia between the myopic and hyperopic RPR from the baseline over 12 months of treatment. Secondary outcomes data include the changes in axial length, peripheral refraction, relative peripheral refraction, the amplitude of accommodation, lag of accommodation, corneal curvature, phoria and stereoacuity.
- Conditions
- Myopia
- Being tested
- DIMS lenses
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DIMS lensesDevice
Defocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children
| Study group | Role | What they receive |
|---|---|---|
| Myopic RPR group | Active comparator | Patients with myopic relative peripheral refraction Receives: Device: DIMS lenses |
| Hyperopic RPR group | Active comparator | Patients with hyperopic relative peripheral refraction Receives: Device: DIMS lenses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cycloplegic refractive error
Refractive error measured after instillation of cycloplegia
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Secondary outcomes (5)
Axial length
Length of the eye
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Peripheral refraction
Refractive errors at peripheral fields
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Amplitude and lag of accommodation
Ability of the eyes to accommodate
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Corneal curvature
Power of the cornea
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Phoria and stereoacuity
Coordination of the two eyes
Measured: Baseline; 2 weeks, 6 months and 12 months post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2023
- Study start1 Dec 2023
- Primary completion3 Apr 2025 (estimated)
- Study completion3 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- More trials run by The Hong Kong Polytechnic UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Hong Kong Polytechnic University
- Sponsor type
- University, hospital or other
- Collaborators
- Centre for Eye and Vision Research, HOYA Lamphun Ltd
- Responsible party
- Principal investigator, LEUNG Tsz Wing, The Hong Kong Polytechnic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06161311
- Sponsor's protocol ID
- HSEARS20221229003-01
- Status last verified
- Nov 2023
- First submitted
- 30 Nov 2023
- Last updated
- 2 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Influence of Baseline Relative Peripheral Refraction in Myopia Control Using Myopic Defocus
- ClinicalTrials.gov ID
- NCT06161311
- Acronym / sponsor ID
- HSEARS20221229003-01
- Conditions
- Myopia
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- The Hong Kong Polytechnic UniversityUniversity, hospital or other
- Collaborators
- Centre for Eye and Vision Research, HOYA Lamphun Ltd
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 3 Apr 2025 (estimated)
- Study completion
- 3 Apr 2025 (estimated)
- First posted
- 7 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Myopia has become a world concern and its prevalence has increased in recent decades. Myopic defocus has been applied for slowing down the axial elongation and myopia progression, which is mainly based on the theory of simultaneous competing defocus and peripheral optics. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses impose myopic defocus in the central or peripheral retina, with myopia progression being retarded by 50% to 60%. However, the optimal amount of myopic defocus has not yet been determined. Relative peripheral refraction (RPR) is used to indicate the difference between peripheral refraction and central refraction. Previous studies showed that retinal shape determined RPR, and baseline RPR may influence the myopia control efficacy using DIMS lenses on myopic children. It is still unclear if any other unknown factor influenced the final myopia control outcome in these young children with myopic RPR at baseline. Unlike our previous study8 that bias on hyperopic RPR children (myopic RPR, n = 27; hyperopic RPR, n = 52), this study is a case-control study with the same sample size for each RPR group. We will also include younger children who are more prone to have myopic RPR and develop high myopia. The results should provide new insight into the myopia control strategy in early-onset myopic children.
In the current study, we will investigate the influence of baseline RPR in myopia retardation using DIMS lenses among young myopic children.
This will ba a 1-year prospective clinical trial. Through G*Power (version 3.1.9.6) calculation, 80 healthy myopic subjects (40 myopic RPR vs 40 hyperopic RPR) aged 5-9 years should be needed. After screened by inclusion criteria, eligible participants will be assigned to wear DIMS lenses for 1 year (12 months, 8 hour per day, 7 days per week). This study includes 5 visits: Visit 1: baseline, Visit 2: lens dispensing, Visit 3: 2-week follow-up, Visit 4: 6-month follow-up, and Visit 5: 12-month follow-up. All eye examinations will be carried out in the Optometry Research Centre (A137), the School of Optometry, the Hong Kong Polytechnic University. The main data collection, including refractive error, axial length, related ocular parameters will be measured at baseline, 6-month and 1-year visits. At the lens dispensing and 2-week follow-up visits, vision acuity testing and computer scanning of posterior eyes will be measured. New DIMS lens will be replaced and upgraded if the equivalent sphere of refraction (SER) is changed or visual acuity change.
The following data will be statistically analyzed. The primary outcome data include the difference in change in SER with cycloplegia between the myopic and hyperopic RPR from the baseline over 12 months of treatment. Secondary outcomes data include the changes in axial length, peripheral refraction, relative peripheral refraction, the amplitude of accommodation, lag of accommodation, corneal curvature, phoria and stereoacuity.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Myopic RPR group | Active comparator | Device: DIMS lensesPatients with myopic relative peripheral refraction |
| Hyperopic RPR group | Active comparator | Device: DIMS lensesPatients with hyperopic relative peripheral refraction |
Who may qualify
- Ages
- 6 to 9 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Age at enrolment: 6-9 years
- Spherical equivalent refraction (SER): -0.75 to -5.00 Diopters (D)
- Astigmatism: -1.50 D or less
- Anisometropia: 1.50 D or less
- Spectacle best-corrected monocular visual acuity (VA): 0.00 logMAR or better
Key exclusion criteria (2 listed)
- Ocular and systemic abnormalities might affect visual functions or refractive development
- Prior use of any drugs or optical devices of myopia control treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DIMS lensesDefocus incorporated multiple segments lenses, which use induce peripheral myopic defocus to control for myopia development in children | Device | Hyperopic RPR group, Myopic RPR group |
Primary outcome
Cycloplegic refractive error
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Refractive error measured after instillation of cycloplegia
5 secondary outcomes
Axial length
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Peripheral refraction
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Amplitude and lag of accommodation
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Corneal curvature
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Phoria and stereoacuity
Time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Myopia
Not yet recruitingObservational study
Corneal Biomechanics and Stromal Tissue Characteristics in Patients Undergoing SMILE
Myopia
Enrolling by invitation
Therapeutic Efficacy of Different Repeated Low-Intensity Red Light Devices and Different Usage Frequencies
Myopia
Not yet recruiting
Clinical Performance and Outcomes After Toric Lens Transition
Astigmatism
Active, not recruitingPhase 4
Odyssey Evaluation in Post LASIK Patients
Cataract
RecruitingPhase 3
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
Myopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing DIMS lenses in people with Myopia, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Tsz Wing Leung, PhD (27664268, jeffrey.TW.leung@polyu.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cycloplegic refractive error (time frame: Baseline; 2 weeks, 6 months and 12 months post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2024.